APA (7th ed.) Citation

Xiang, Z., Ma, L., Li, Z., Fu, Y., & Pan, Y. Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Xiang, Zuojuan, Ling Ma, Zhengxiong Li, Yingzhou Fu, and Yong Pan. Cost-effectiveness Analysis of First-line Combination Chemotherapy Regimens for Metastatic Pancreatic Cancer and Evidence-based Pricing Strategy of Liposomal Irinotecan in China. Frontiers Media S.A.

MLA (9th ed.) Citation

Xiang, Zuojuan, et al. Cost-effectiveness Analysis of First-line Combination Chemotherapy Regimens for Metastatic Pancreatic Cancer and Evidence-based Pricing Strategy of Liposomal Irinotecan in China. Frontiers Media S.A.